Tools for Practice Outils pour la pratique


#10 Antioxidant Vitamin Cure-Alls: Will Good Theories Ever Die?


CLINICAL QUESTION
QUESTION CLINIQUE
Does daily supplementation of antioxidant vitamins (A, E, and C) decrease mortality in the general population?


BOTTOM LINE
RÉSULTAT FINAL
The current evidence does not support the use of antioxidant supplementation, and patients should be dissuaded from using beta-carotene, vitamin E, and perhaps high-dose vitamin A, as they appear to increase mortality by about 1 in every 250 over ~5 years.  



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
One Cochrane review1 of 78 Randomized Controlled Trials (RCTs) with 296,707 patients (~75% healthy participants, ~25% pre-existing condition):  
  • Focusing on high-quality RCTs: 
    • Antioxidants increased mortality with a Relative Risk (RR) of 1.04 (1.01-1.07), Number Needed to Harm (NNH)=238. 
    • Specifically: 
      • Beta-carotene (pro-vitamin A): RR 1.05 (1.01-1.09). 
      • Vitamin E: RR 1.03 (1.00-1.05). 
    • No statistically significant difference in mortality for: 
      • Vitamin A, all doses: RR 1.07 (0.97-1.18). 
        • High-dose vitamin A appears to increase mortality (p=0.002). 
        • High-dose not clearly defined, but appears to be >5000 IU. 
      • Vitamin C: RR 1.02 (0.98-1.07). 
      • Selenium: RR 0.97 (0.91-1.03). 
    • If baseline mortality risk were around 10% over 3.5 years, about one in every 100 to 250 people taking antioxidants would die because of the supplements. 
  • Other meta-analyses report similar results. Examples: 
    • Antioxidant vitamins do not reduce the incidence of cardiovascular disease or cancer when taken for primary prevention.2 
    • Beta-carotene: Statistically significant increased mortality (NNH=167-326).2-4 
    • Vitamin E: 
      • No difference in mortality in 101,343 healthy individuals: RR 1.01 (0.98-1.04).2 
      • High-dose (>400 IU): Statistically significant increased mortality (NNH=257).5,6
Context:  
  • While theories and previous observational studies suggested potential benefit with antioxidant vitamins, this has been disproven by higher-level evidence. 
    • Theories of disease and treatment/prevention are common in medicine. We must guard against the superficial appeal of these theories and rely on evidence of benefit or harm to guide the care of our patients. 
updated aug 21 2016 by ricky


Latest Tools for Practice
Derniers outils pour la pratique

#359 Topical corticosteroids for atopic dermatitis - More than skin deep

What are the benefits/harms of topical corticosteroids for atopic dermatitis in adults/children?
Read Lire 0.25 credits available Crédits disponibles

#358: Any berry good solutions to preventing UTIs: Cranberries?

Do cranberry products prevent recurrent urinary tract infections (UTIs)?
Read Lire 0.25 credits available Crédits disponibles

#357: Overcoming Resistance: Antipsychotics for difficult to treat depression

In patients with treatment-resistant depression, is adding an atypical antipsychotic to current therapy safe and effective?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Christina Korownyk MD CCFP
  • G. Michael Allan MD CCFP

1. Bjelakovic G, Nikolova D, Gluud LL, et al. Cochrane Database Syst Rev. 2012; 3:CD007176.

2. Fortmann SP, Burda BU, Senger C, et al. Ann Intern Med. 2013; 159:824-34.

3. Vivekananthan DP, Penn MS, Sapp SK, et al. Lancet. 2003; 361:2017-23.

4. Teo KK. ACP J Club. 2004; 140:45.

5. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Ann Intern Med. 2005; 142:37-46.

6. Simon JA. ACP J Club. 2005; 143:1.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.